307 related articles for article (PubMed ID: 25791169)
21. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
22. Erasers of histone acetylation: the histone deacetylase enzymes.
Seto E; Yoshida M
Cold Spring Harb Perspect Biol; 2014 Apr; 6(4):a018713. PubMed ID: 24691964
[TBL] [Abstract][Full Text] [Related]
23. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
24. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.
Kong Y; Tannous P; Lu G; Berenji K; Rothermel BA; Olson EN; Hill JA
Circulation; 2006 Jun; 113(22):2579-88. PubMed ID: 16735673
[TBL] [Abstract][Full Text] [Related]
25. Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure.
Evans LW; Ferguson BS
Nutrients; 2018 Aug; 10(8):. PubMed ID: 30126190
[TBL] [Abstract][Full Text] [Related]
26. Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy.
Trivedi CM; Lu MM; Wang Q; Epstein JA
J Biol Chem; 2008 Sep; 283(39):26484-9. PubMed ID: 18625706
[TBL] [Abstract][Full Text] [Related]
27. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.
Ooi JY; Tuano NK; Rafehi H; Gao XM; Ziemann M; Du XJ; El-Osta A
Epigenetics; 2015; 10(5):418-30. PubMed ID: 25941940
[TBL] [Abstract][Full Text] [Related]
28. Heart failure: the pivotal role of histone deacetylases.
Hewitson R; Dargan J; Collis D; Green A; Moorjani N; Ohri S; Townsend PA
Int J Biochem Cell Biol; 2013 Feb; 45(2):448-53. PubMed ID: 23178536
[TBL] [Abstract][Full Text] [Related]
29. NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs.
Vaquero A; Sternglanz R; Reinberg D
Oncogene; 2007 Aug; 26(37):5505-20. PubMed ID: 17694090
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of NAD+ dependent histone deacetylases (sirtuins).
Neugebauer RC; Sippl W; Jung M
Curr Pharm Des; 2008; 14(6):562-73. PubMed ID: 18336301
[TBL] [Abstract][Full Text] [Related]
31. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy.
Eom GH; Nam YS; Oh JG; Choe N; Min HK; Yoo EK; Kang G; Nguyen VH; Min JJ; Kim JK; Lee IK; Bassel-Duby R; Olson EN; Park WJ; Kook H
Circ Res; 2014 Mar; 114(7):1133-43. PubMed ID: 24526703
[TBL] [Abstract][Full Text] [Related]
32. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
33. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.
Dewanjee S; Vallamkondu J; Kalra RS; Chakraborty P; Gangopadhyay M; Sahu R; Medala V; John A; Reddy PH; De Feo V; Kandimalla R
Cells; 2021 May; 10(6):. PubMed ID: 34071497
[TBL] [Abstract][Full Text] [Related]
34. Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure.
Lkhagva B; Lin YK; Kao YH; Chazo TF; Chung CC; Chen SA; Chen YJ
Pharmacology; 2015; 96(3-4):184-91. PubMed ID: 26304494
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats.
Kang SH; Seok YM; Song MJ; Lee HA; Kurz T; Kim I
Mol Pharmacol; 2015 May; 87(5):782-91. PubMed ID: 25667225
[TBL] [Abstract][Full Text] [Related]
36. Roles and post-translational regulation of cardiac class IIa histone deacetylase isoforms.
Weeks KL; Avkiran M
J Physiol; 2015 Apr; 593(8):1785-97. PubMed ID: 25362149
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway.
Xu Z; Tong Q; Zhang Z; Wang S; Zheng Y; Liu Q; Qian LB; Chen SY; Sun J; Cai L
Clin Sci (Lond); 2017 Aug; 131(15):1841-1857. PubMed ID: 28533215
[TBL] [Abstract][Full Text] [Related]
38. Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy.
Ferguson BS; Harrison BC; Jeong MY; Reid BG; Wempe MF; Wagner FF; Holson EB; McKinsey TA
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9806-11. PubMed ID: 23720316
[TBL] [Abstract][Full Text] [Related]
39. [The mechanism underlying histone deacetylases regulating cardiac hypertrophy].
Ren L; Wu XS; Li YQ
Yi Chuan; 2020 Jun; 42(6):536-547. PubMed ID: 32694112
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
